Abstract
Oligonucleotides—short, synthetic nucleotide strands that can be used as drugs to modulate gene expression—were at the heart of two deals inked in December. Vertex Pharmaceuticals will pay Entrada Therapeutics $250 million and up to $485 million later to advance treatments for myotonic dystrophy type 1, including a preclinical oligonucleotide therapy from Entrada that potentially restores muscle function. And GSK will pay Wave Life Sciences $170 million up front plus future milestones and royalties as part of a pact to advance up to 11 oligonucleotide programs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
